Pharma manufacturer Teva will work with biotech company Insilico to develop more efficient production processes for its biopharmaceutical therapeutics.
Collaboration
Teva will apply Insilico’s technology for predictive biomanufacturing in a move to generate high-quality data and help bring its therapies to market faster.
Insilico’s Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms in combination with flexible process models and artificial intelligence to create optimisd production processes by computational simulations.
“By complementing our process development capabilities with Insilico’s unique technology for digital bioprocess development we can accomplish robust and efficient production of our biologics pipeline faster”, said Jason Bock, VP of Biologics CMC at Teva. “Saving experimental efforts and time perfectly fits the accelerated timelines in clinical development that we are seeing now and even more in the future.”
Klaus Mauch, CEO of Insilico Biotechnology, added: “We are proud to support Teva with our predictive solutions to speed-up the key steps in bioprocess development. The use of Insilico Digital Twins is able to transform the enormous wealth of process data generated every day into measurable improvements. We are absolutely convinced that this collaboration is a major step in predictive biomanufacturing and towards the future of biologics production.”